Lowe Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Lowe Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$3.84K	Hold	180	–	–	﹤0.01%	305
2025 Q2	$3.88K	Hold	180	–	–	﹤0.01%	303
2025 Q1	$2.99K	Hold	180	–	–	﹤0.01%	319
2024 Q4	$3.3K	Hold	180	–	–	﹤0.01%	308
2024 Q3	$2.77K	Hold	180	–	–	﹤0.01%	271
2024 Q2	$2.92K	Hold	180	–	–	﹤0.01%	268
2024 Q1	$3.33K	Hold	180	–	–	﹤0.01%	262
2023 Q4	$5.64K	Hold	180	–	–	﹤0.01%	242
2023 Q3	$3.75K	Hold	180	–	–	﹤0.01%	248
2023 Q2	$4.31K	Hold	180	–	–	﹤0.01%	274
2023 Q1	$3.39K	Hold	180	–	–	﹤0.01%	274
2022 Q4	$2.87K	Hold	180	–	–	﹤0.01%	287
2022 Q3	$3K	Hold	180	–	–	﹤0.01%	265
2022 Q2	$3K	Hold	180	–	–	﹤0.01%	254
2022 Q1	$4K	Hold	180	–	–	﹤0.01%	249
2021 Q4	$4K	Hold	180	–	–	﹤0.01%	235
2021 Q3	$3K	Hold	180	–	–	﹤0.01%	239
2021 Q2	$4K	Hold	180	–	–	﹤0.01%	218
2021 Q1	$5K	Buy	+180	New	+$7.92K	﹤0.01%	202

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Lowe Wealth Advisors's ACAD Position: Q3 2025 in Review

Lowe Wealth Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2025 at 180 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #305.

Lowe Wealth Advisors first reported a position in ACAD in Q1 2021 and has held it in 19 quarters since. The position peaked at $5.64K in Q4 2023. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

Lowe Wealth Advisors held 180 shares of Acadia Pharmaceuticals worth $3.84K as of Q3 2025.
Lowe Wealth Advisors left its Acadia Pharmaceuticals share count unchanged in Q3 2025.
Acadia Pharmaceuticals made up ﹤0.01% of Lowe Wealth Advisors's portfolio in Q3 2025, its #305 holding.
Lowe Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
Lowe Wealth Advisors's Acadia Pharmaceuticals position peaked at $5.64K in Q4 2023.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Lowe Wealth Advisors's 13F filing for Q3 2025, filed 16 Oct 2025.